Cargando…
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients has been high-dose chemotherapy fo...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424456/ https://www.ncbi.nlm.nih.gov/pubmed/37580826 http://dx.doi.org/10.1186/s40164-023-00432-z |